Furthermore, ongoing clinical trials are assessing the combination of anti-CDK4/6 treatments with insulin-like growth factor inhibition (trial no. NCT03099174) or with EGFR inhibition (trial no. NCT03065387) in various tumor types. Here, EGFR is linked to neoplasm.